Galapagos identifies possible new osteoarthritis drug
BRUSSELS (Reuters) - Belgian drug developer Galapagos is in line for an undisclosed milestone payment after identifying a possible oral treatment for osteoarthritis as part of its collaboration with France's Servier, it said on Tuesday.
"This achievement also marks the third alliance with a different pharma partner in which Galapagos has identified a pre-clinical candidate," Onno van de Stolpe, Chief Executive Officer of Galapagos, said in a statement.
(Reporting By Ben Deighton)
- Canada's parliament attacked, soldier fatally shot nearby |
- NOAA employee charged with stealing U.S. dam information
- Sweden gets two new sightings, as hunt for undersea intruder goes on
- Canada probes Michael Zehaf-Bibeau as possible suspect in Ottawa shooting: source
- Special Report: Traffickers use abductions, prison ships to feed Asian slave trade